Tag: CoronaRemediesIPO

Corona Remedies made a strong debut on Dalal Street on Monday, December 15, 2025, with shares opening at ₹1,470 on NSE and ₹1,452 on BSE, against the IPO price of ₹1,062, marking a 38% listing gain.

The ₹655-crore IPO, fully an offer-for-sale, was heavily oversubscribed, reflecting robust investor interest. Grey market data had also suggested strong demand ahead of listing.

The Gujarat-based pharma firm specializes in women’s healthcare and cardiometabolic medicines. Early trading showed sustained gains, indicating positive market sentiment for the stock.

The Corona Remedies IPO, priced between ₹1,008–₹1,062 per share, saw robust demand, closing Day 3 with a 32× overall subscription.

The Non-Institutional Investor (NII) segment led the frenzy, oversubscribed 107×, while retail and qualified institutional buyers also showed strong interest.

Grey Market Premium (GMP) surged to around ₹30 per share, indicating high listing expectations. The IPO, valued at ₹655 crore through an offer-for-sale, reflects strong market confidence.

Investors are keenly watching the listing, but experts advise caution given the steep oversubscription and potential volatility post-listing.

Corona Remedies launched its ₹655 crore IPO on December 8 with a price band of ₹1,008–1,062 per share.

On the first day, the issue saw 33% subscription, with 14.75 lakh shares bid against 45.71 lakh shares on offer. The grey-market is trading at a premium of around ₹290, indicating positive investor sentiment.

The company reported FY25 revenue of ₹1,196 crore, EBITDA of ₹246 crore, and a profit after tax of ₹149.43 crore, reflecting strong financials.

The subscription window closes December 10, with listing expected on BSE/NSE around December 15, making it a closely watched IPO.